AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21842214 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training
Number of subjects: 37
Study 19179550 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal jugular access
Number of subjects: 403
Study 19179550 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclavian access
Number of subjects: 403
Study 19179550 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalic vein access
Number of subjects: 403
Study 19179550 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided subclavian insertion
Number of subjects: 403
Study 17233778 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexually explicit video (N = 20)
Number of subjects: 58
Study 17233778 — intervention group
Group type: COMPARATOR
Intervention: Humor video (N = 19)
Number of subjects: 58
Study 17233778 — intervention group
Group type: COMPARATOR
Intervention: Neutral video (N = 19)
Number of subjects: 58
Study 14668578 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine 500 mg twice daily
Number of subjects: 17
Study 14668578 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine 250 mg twice daily
Number of subjects: 17
Study 11772700 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (N=24)
Number of subjects: 51
Study 11772700 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (N=27)
Number of subjects: 51
Study 11772700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 10343725 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised Sensory Environment (ISE) intervention
Number of subjects: 0
Study 7496940 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 139
Study 7496940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 2589261 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteosynthesis (n = 26)
Number of subjects: 53
Study 2589261 — intervention group
Group type: COMPARATOR
Intervention: No osteosynthesis (n = 27)
Number of subjects: 53
Study 2589261 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups pooled
Number of subjects: 53
Study 165157 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue with light exposure
Number of subjects: 56
Study 165157 — intervention group
Group type: EXPERIMENTAL
Intervention: Proflavine
Number of subjects: 56
Study 165157 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral red
Number of subjects: 56
Study 165157 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 56
Study 31189356 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate (group I, n=100)
Number of subjects: 201
Study 31189356 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric hydroxide polymaltose complex (group II, n=101)
Number of subjects: 201
Study 28403127 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 40
Study 28403127 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 40
Study 26520216 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) in combination with Treatment as Usual (TAU)
Number of subjects: 52
Study 26520216 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) alone
Number of subjects: 52
Study 24180719 — intervention group
Group type: EXPERIMENTAL
Intervention: Video and usual care (Group V)
Number of subjects: 143
Study 24180719 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Group C)
Number of subjects: 143
Study 21315215 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,000-U anti-Xa certoparin once daily
Number of subjects: 542
Study 21315215 — intervention group
Group type: COMPARATOR
Intervention: 5,000-IU UFH 3 times a day
Number of subjects: 542
Study 18996639 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B therapy (group B)
Number of subjects: 106
Study 18996639 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group A)
Number of subjects: 106
Study 16427339 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pulse-spray thrombolysis (rt-PA, 15 mg/h for 2h)
Number of subjects: 121
Study 16427339 — intervention group
Group type: COMPARATOR
Intervention: Low-dose infusion (rt-PA, 0.5 mg/h for 48 h)
Number of subjects: 121
Study 16427339 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pulse-spray thrombolysis
Number of subjects: 121
Study 16427339 — intervention group
Group type: COMPARATOR
Intervention: Low-dose infusion
Number of subjects: 121
Study 14506910 — intervention group
Group type: EXPERIMENTAL
Intervention: nimesulide (100mg)
Number of subjects: 30
Study 14506910 — intervention group
Group type: COMPARATOR
Intervention: celecoxib (200mg)
Number of subjects: 30
Study 14506910 — intervention group
Group type: COMPARATOR
Intervention: rofecoxib (25mg)
Number of subjects: 30
Study 10718829 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted ethanol (0.45 g ethanol/kg b.w.)
Number of subjects: 8
Study 10718829 — intervention group
Group type: COMPARATOR
Intervention: Water (150 ml doses)
Number of subjects: 8
Study 8827427 — intervention group
Group type: EXPERIMENTAL
Intervention: HP‐RHEUM (computer-assisted interactive videodisc instruction)
Number of subjects: 113
Study 8827427 — intervention group
Group type: COMPARATOR
Intervention: Traditional classroom instruction (control)
Number of subjects: 113
Study 1401653 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine
Number of subjects: 8
Study 1401653 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine (60 mg)
Number of subjects: 8
Study 1401653 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine (300 mg)
Number of subjects: 8
Study 1401653 — intervention group
Group type: COMPARATOR
Intervention: Loratadine (10 mg)
Number of subjects: 8
Study 1401653 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine
Number of subjects: 8
Study 3858912 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microgram PGE1‐carbinol
Number of subjects: 15
Study 3858912 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms PGE1‐carbinol
Number of subjects: 15
Study 3858912 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms PGE1‐carbinol
Number of subjects: 15
Study 3858912 — intervention group
Group type: EXPERIMENTAL
Intervention: 55 micrograms PGE2
Number of subjects: 15
Study 3858912 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms fenoterol
Number of subjects: 15
Study 31285094 — intervention group
Group type: EXPERIMENTAL
Intervention: Margin <3 mm (n=47)
Number of subjects: 112
Study 31285094 — intervention group
Group type: EXPERIMENTAL
Intervention: Margin ≥3 mm to <8 mm (n=48)
Number of subjects: 112
Study 31285094 — intervention group
Group type: EXPERIMENTAL
Intervention: Margin ≥8 mm (n=17)
Number of subjects: 112
Study 31285094 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis of margins <8 mm (group 1 and 2)
Number of subjects: 112
Study 31285094 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival, disease-free and metastasis-free survivals
Number of subjects: 112
Study 29374526 — intervention group
Group type: EXPERIMENTAL
Intervention: Small monetary incentives ($1/session, maximum of $5/week)
Number of subjects: 75
Study 29374526 — intervention group
Group type: EXPERIMENTAL
Intervention: Charitable donations in the same amount ($1/session, maximum of $5/week)
Number of subjects: 75
Study 29374526 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 75
Study 27724929 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic inflow occlusion (Pringle maneuver)
Number of subjects: 114
Study 27724929 — intervention group
Group type: COMPARATOR
Intervention: No hepatic inflow occlusion
Number of subjects: 114
Study 24621953 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) given once a month (IPTm)
Number of subjects: 740
Study 24621953 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) given once a school term (IPTst)
Number of subjects: 740
Study 24621953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 740
Study 22316868 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly-designed insole
Number of subjects: 30
Study 22316868 — intervention group
Group type: COMPARATOR
Intervention: Commercially available insole 1
Number of subjects: 30
Study 22316868 — intervention group
Group type: COMPARATOR
Intervention: Commercially available insole 2
Number of subjects: 30
Study 22316868 — intervention group
Group type: COMPARATOR
Intervention: Barefoot condition
Number of subjects: 30
Study 20613689 — intervention group
Group type: EXPERIMENTAL
Intervention: APEC (Anesthesia Preoperative Evaluation Clinic)
Number of subjects: 207
Study 20613689 — intervention group
Group type: COMPARATOR
Intervention: Ward assessment
Number of subjects: 207
Study 17390144 — intervention group
Group type: EXPERIMENTAL
Intervention: Balsalazide 2.25 g daily for 10 days every month plus VSL#3 450 billions/day for 15 days every month
Number of subjects: 30
Study 17390144 — intervention group
Group type: COMPARATOR
Intervention: VSL#3 alone 450 billions/day for 15 days every month
Number of subjects: 30
Study 15668539 — intervention group
Group type: EXPERIMENTAL
Intervention: fosamprenavir/RTV 700/100 mg (arm B)
Number of subjects: 33
Study 15668539 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV/RTV/fosamprenavir 400/100/700 mg (arm C)
Number of subjects: 33
Study 15668539 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV/RTV 400/100 mg (arm A)
Number of subjects: 33
Study 12014729 — intervention group
Group type: COMPARATOR
Intervention: Interferon alone (6 MU three times a week)
Number of subjects: 114
Study 12014729 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebotomy until iron depletion followed by interferon (6 MU three times a week)
Number of subjects: 114
Study 9773135 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 3 mg
Number of subjects: 120
Study 9773135 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg
Number of subjects: 120
Study 9773135 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 120
Study 9773135 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 120
Study 7636540 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexverapamil (escalated from 240 to 1,200 mg/m2/d) combined with EPOCH chemotherapy
Number of subjects: 154
Study 7636540 — intervention group
Group type: COMPARATOR
Intervention: EPOCH chemotherapy alone
Number of subjects: 154
Study 7636540 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexverapamil
Number of subjects: 154
Study 2247813 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy for gallbladder stones
Number of subjects: 0
Study 2247813 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy for bile duct stones
Number of subjects: 0
Study 345414 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylated analogues of prostaglandin E2 administered orally
Number of subjects: 117
Study 345414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 30449531 — intervention group
Group type: EXPERIMENTAL
Intervention: Drift-diffusion model-derived attention bias indices
Number of subjects: 70
Study 30449531 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated attention retraining procedure
Number of subjects: 70
Study 28663304 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 72
Study 28663304 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Number of subjects: 72
Study 28663304 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-meal tolerance test
Number of subjects: 72
Study 26429629 — intervention group
Group type: EXPERIMENTAL
Intervention: ORALMENT (L-menthol oral administration)
Number of subjects: 20
Study 26429629 — intervention group
Group type: EXPERIMENTAL
Intervention: SKINMENT (L-menthol skin administration)
Number of subjects: 20
Study 26429629 — intervention group
Group type: COMPARATOR
Intervention: ORALCON (control for oral administration)
Number of subjects: 20
Study 26429629 — intervention group
Group type: COMPARATOR
Intervention: SKINCON (control for skin administration)
Number of subjects: 20
Study 23883424 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL syringe
Number of subjects: 48
Study 23883424 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL syringe
Number of subjects: 48
Study 23883424 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL syringe
Number of subjects: 48
Study 23883424 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mL syringe
Number of subjects: 48
Study 21834476 — intervention group
Group type: EXPERIMENTAL
Intervention: Oversewing the staple line with a polypropylene 3‐0 running suture (Group A)
Number of subjects: 100
Study 21834476 — intervention group
Group type: COMPARATOR
Intervention: No oversewing of the staple line (Group B)
Number of subjects: 100
Study 19523617 — intervention group
Group type: EXPERIMENTAL
Intervention: Single medium continuously, without medium renewal on day 3
Number of subjects: 893
Study 19523617 — intervention group
Group type: COMPARATOR
Intervention: Sequential media
Number of subjects: 893
Study 16643233 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/ml levobupivacaine via CEI (15 mg/h)
Number of subjects: 82
Study 16643233 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/ml levobupivacaine via CEI (15 mg/h)
Number of subjects: 82
Study 16643233 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/ml levobupivacaine via PCEA (5 mg bolus, 20 min lockout)
Number of subjects: 82
Study 16643233 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/ml levobupivacaine via PCEA (5 mg bolus, 20 min lockout)
Number of subjects: 82
Study 16643233 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 82
Study 15292626 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of cognitive-behavioral therapy and ethyl loflazepate (2 mg daily) for 6 weeks
Number of subjects: 42
Study 15292626 — intervention group
Group type: EXPERIMENTAL
Intervention: Antianxiety agent only (ethyl loflazepate) for 6 weeks
Number of subjects: 42
Study 15292626 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 42
Study 15292626 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment group
Number of subjects: 42
Study 15292626 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication only group
Number of subjects: 42
Study 11321637 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-study of chess positions (500 positions over several months, 15-30 minutes daily)
Number of subjects: 2
Study 11321637 — intervention group
Group type: EXPERIMENTAL
Intervention: Chunk construction based on the neighbourhood of associated pieces
Number of subjects: 2
Study 11321637 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency-based correlative association process
Number of subjects: 2
Study 9008371 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy-congruent distortion of midterm grades when expectancy and liking matched.
Number of subjects: 0
Study 9008371 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy-discontinued condition when expectancy and liking mismatched.
Number of subjects: 0
Study 9008371 — intervention group
Group type: EXPERIMENTAL
Intervention: Order of expectancy and liking information.
Number of subjects: 0
Study 8509240 — intervention group
Group type: EXPERIMENTAL
Intervention: Bench Stepping (BS) at 30 and 32 step cycles.min‐1 with bench heights (BH) of 15.2, 30.4, 25.4, and 30.5 cm.
Number of subjects: 28
Study 8509240 — intervention group
Group type: COMPARATOR
Intervention: Treadmill walking/running (TM)
Number of subjects: 28
Study 3323852 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential oestrogen/progestogen therapy (4 mg, 2 mg, and 1 mg 17 beta‐oestradiol combined with 1 mg norethisterone acetate)
Number of subjects: 87
Study 3323852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 30992026 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretical geometric model developed based on specific morphometrics from C-T sections.
Number of subjects: 9
Study 28060713 — intervention group
Group type: EXPERIMENTAL
Intervention: Boost.SH
Number of subjects: 0
Study 28060713 — intervention group
Group type: COMPARATOR
Intervention: AdaBoost
Number of subjects: 0
Study 28060713 — intervention group
Group type: COMPARATOR
Intervention: Multiview kernel learning algorithm
Number of subjects: 0
Study 26777721 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time daily patient feedback to providers along with provider coaching and revisits of patients not reporting optimal satisfaction with their care.
Number of subjects: 0
Study 26777721 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving real-time feedback).
Number of subjects: 0
Study 25178594 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin at a dose of 10mg/kg/day for 7 days
Number of subjects: 60
Study 25178594 — intervention group
Group type: COMPARATOR
Intervention: Cefixime at a dose of 20mg/kg/day in two divided doses for 14 days
Number of subjects: 60
Study 21819813 — intervention group
Group type: EXPERIMENTAL
Intervention: Thought Records (TRs)
Number of subjects: 91
Study 21819813 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Experiments (BEs)
Number of subjects: 91
Study 21819813 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 91
Study 20463186 — intervention group
Group type: EXPERIMENTAL
Intervention: RTX 2 x 500 mg
Number of subjects: 346
Study 20463186 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose escalation (2 x 500 mg to 2 x 1000 mg)
Number of subjects: 346
Study 20463186 — intervention group
Group type: EXPERIMENTAL
Intervention: RTX 2 x 1000 mg
Number of subjects: 346
Study 20463186 — intervention group
Group type: EXPERIMENTAL
Intervention: All RTX regimens
Number of subjects: 346
Study 16855773 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng (KRG) 1,000 mg (3 times daily)
Number of subjects: 60
Study 16855773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16163531 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (150 mg SR)
Number of subjects: 26
Study 16163531 — intervention group
Group type: EXPERIMENTAL
Intervention: Methamphetamine (0, 15, and 30 mg)
Number of subjects: 26
Study 16163531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 11921421 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan 50 mg daily
Number of subjects: 80
Study 11921421 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study 10091831 — intervention group
Group type: EXPERIMENTAL
Intervention: i.c. adenosine (2.4 mg/min for 10 min starting 20 min before the first occlusion)
Number of subjects: 30
Study 10091831 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 30
Study 7594412 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide diuretics or beta-blockers (first- or second-line drugs)
Number of subjects: 0
Study 7594412 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic treatment
Number of subjects: 0
Study 7594412 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of diastolic hypertension
Number of subjects: 0
Study 7594412 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of isolated systolic hypertension
Number of subjects: 0
Study 2221964 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual refeeding after rehydration
Number of subjects: 62
Study 2221964 — intervention group
Group type: COMPARATOR
Intervention: Abrupt refeeding after rehydration
Number of subjects: 62
Study 2221964 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose free soya based formula
Number of subjects: 62
Study 392739 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfamethizole
Number of subjects: 112
Study 392739 — intervention group
Group type: COMPARATOR
Intervention: Sulfamethoxazole
Number of subjects: 112
Study 31654643 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine‐epinephrine
Number of subjects: 40
Study 31654643 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine‐felypressin
Number of subjects: 40
Study 31654643 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 40
Study 31238886 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnership intervention (video consultations between cancer patient, general practitioner, and oncologist)
Number of subjects: 278
Study 28577292 — intervention group
Group type: EXPERIMENTAL
Intervention: Teneligliptin 20 mg/day for 12 weeks
Number of subjects: 25
Study 28577292 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25
Study 26446779 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored interventions
Number of subjects: 7
Study 23356388 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversations regarding dietary habits
Number of subjects: 23
Study 23356388 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversations regarding physical activity
Number of subjects: 23
Study 23356388 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversations regarding physical examinations
Number of subjects: 23
Study 23356388 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversations regarding child engagement
Number of subjects: 23
Study 23356388 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversations regarding language skills
Number of subjects: 23
Study 20204975 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention (peer-modelling materials, daily pedometer goals, rewards)
Number of subjects: 386
Study 20204975 — intervention group
Group type: EXPERIMENTAL
Intervention: No-rewards intervention (peer-modelling materials, daily pedometer goals, no rewards)
Number of subjects: 386
Study 20204975 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group, wore pedometers only)
Number of subjects: 386
Study 20204975 — intervention group
Group type: EXPERIMENTAL
Intervention: No-rewards intervention (after taper phase)
Number of subjects: 386
Study 20204975 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention (after taper phase)
Number of subjects: 386
Study 19751560 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone
Number of subjects: 77